Plus Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in the development of targeted radiotherapeutics and diagnostic services for central nervous system (CNS) cancers. The company’s primary products include REYOBIQ™ (rhenium Re-186 obisbemeda), an investigational liposomal radiopharmaceutical aimed at treating recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. It also offers CNSide®, a molecular diagnostic cerebrospinal fluid (CSF) assay platform designed to support rapid diagnosis and treatment monitoring of CNS cancers. Additionally, Plus Therapeutics is developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188NL-BAM) for treating solid organ cancers including primary and secondary liver cancers. Recent major developments include the commercial launch of the CNSide CSF diagnostics platform, receiving the first national coverage agreement with UnitedHealthcare effective September 2025, covering over 51 million people in the U.S., and achieving CLIA accreditation for its Houston laboratory. The company demonstrated positive interim Phase 1 clinical trial results for REYOBIQ™ in leptomeningeal metastases, showing favorable safety and efficacy signals. Plus Therapeutics has strengthened its financial position with a $17.6 million Cancer Prevention and Research Institute of Texas (CPRIT) grant, advanced private placements, and regained Nasdaq listing compliance. In 2025, it also appointed Kyle Guse to its Board of Directors, enhancing its governance with his financial and legal expertise. Founded in 2014, Plus Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, focusing on difficult-to-treat cancers of the CNS and solid organs. It leverages proprietary nanoliposome technology to deliver targeted radioisotope therapies directly to tumors using convection-enhanced delivery (CED) and standard medical access techniques such as Ommaya reservoirs. The company’s products and clinical programs target adult and pediatric patients with rare and challenging cancers, conducting clinical trials across the U.S. and collaborating with leading cancer centers. Plus Therapeutics combines innovation in radiopharmaceutical drug delivery with advanced diagnostic platforms to improve patient outcomes in oncology.
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
Plus Therapeutics Appoints Eric J. Daniels, M.D.